CDK12-IN-E9

• CAT Number: I017214
• CAS Number: 2020052-55-3
• Molecular Formula: C₂₄H₃₀N₆O₂
• Molecular Weight: 434.53
• Purity: ≥95%
• IUPAC Name: N-[3-[[3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]phenyl]prop-2-enamide
• InChI: InChI=1S/C24H30N6O2/c1-3-17-16-25-30-22(26-18-8-7-9-19(14-18)27-23(32)4-2)15-21(28-24(17)30)29-12-6-5-10-20(29)11-13-31/h4,7-9,14-16,20,26,31H,2-3,5-6,10-13H2,1H3,(H,27,32)/t20-/m0/s1
• InChIKey: CDCHESFKYUNJPV-FQEVSTJZSA-N
• SMILES: CCC1=C2N=C(C=C(N2N=C1)NC3=CC(=CC=C3)NC(=O)C=C)N4CCCC[C@H]4CCO

CDK12-IN-E9 (Cat.No:I017214) is a highly selective and potent CDK12 inhibitor. CDK12-IN-E9 inhibits CDK12 with an IC50 of 5.9 nM, while showing little or no activity against other CDK family members. CDK12 plays a crucial role in regulating gene expression and DNA damage response, making CDK12-IN-E9 a promising therapeutic agent for cancer treatment. Preclinical studies have shown promising results in targeting CDK12 with inhibitors like CDK12-IN-E9 for cancer therapy.

Reference

[1]. Gao Y, et al. Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.